Related Experiment Video
Updated: Jun 14, 2026
08:01
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
Phospholipase A2s: developing drug targets for atherosclerosis.
1GlaxoSmithKline, 291 Knightsfield, Welwyn Garden City, Hertfordshire AL8 7NH, UK. keith@suckling291.freeserve.co.uk
Atherosclerosis
|April 6, 2010
Summary
Phospholipase A2 inhibitors show promise for treating atherosclerosis. Clinical trials for darapladib and varespladib highlight distinct targets and potential therapeutic benefits in cardiovascular disease management.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Medicine
Background:
- Atherosclerosis is a complex inflammatory disease.
- Phospholipases, particularly phospholipase A2 (PLA2) enzymes, play a role in atherogenesis.
- PLA2 enzymes are implicated in lipid metabolism and inflammatory pathways relevant to cardiovascular health.
Purpose of the Study:
- To review the scientific basis for targeting phospholipase A2 enzymes in atherosclerosis.
- To discuss the distinct roles of lipoprotein-associated PLA2 (Lp-PLA2) and secreted PLA2s (sPLA2s) in atherogenesis.
- To evaluate the clinical trial data supporting the development of PLA2 inhibitors.
Main Methods:
- Review of preclinical and clinical data on PLA2 inhibitors.
- Analysis of in vitro and in vivo studies on PLA2 function in atherosclerosis.
- Examination of Phase 2 clinical trial results for darapladib and varespladib.
Main Results:
- Phase 2 clinical trials for darapladib (Lp-PLA2 inhibitor) and varespladib (sPLA2 inhibitor) have been published.
- Distinct biological roles and therapeutic potentials exist for targeting Lp-PLA2 versus sPLA2s.
- Data support the progression of these inhibitors into Phase 3 clinical trials.
Conclusions:
- Targeting specific phospholipase A2 enzymes represents a promising therapeutic strategy for atherosclerosis.
- Further clinical investigation is warranted for both Lp-PLA2 and sPLA2 inhibitors.
- Emerging research also indicates potential for cytosolic PLA2 targets.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:38Inflammation
Overview
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: